Результаты поиска

Ход работы сессии 28th Европейский конгресс педиатрической ремуматологии (ПСР) 2022) Прага, Чешская Республика. 20-23 сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Синдром PEEMS: 2026 Обновленная информация по диагностике, статистике рисков и управлению.

Синдром PEMS — это угрожающий жизни синдром, вызванный плазменной неоплазмой. Основными критериями для этого синдрома являются полиномропатическое расстройство клональных клеток (ПХД), склеротические повреждения костей, повышенный сосудистый эндотелиальный фактор роста и наличие болезни Каслмана. Незначительные особенности включают в себя органомегалию, эндокринопатию, характерные изменения кожи, папилледему, вневаскулярную перегрузку объема и тромбоцитоз. Диагноз синдрома POEMS three основных критериев, two в том числе полиномропаты и клональные плазменные клетки, и по крайней мере one незнач

Совпадение в полном тексте источника
… Both our experience and the literature would support that single agent intravenous gamma globulin (IVIG) or plasmapheresis is not helpful. One more recent report, however, described reduction in serum VEGF and clinical improvement with single agent IVIG. …

Application of cell-derived exosomes in the hematological malignancies therapy.

Exosomes are small membrane vesicles of endocytic origin that are produced by both tumor and normal cells and can be found in physiological fluids like plasma and cell culture supernatants. They include cytokines, growth factors, proteins, lipids, RNAs, and metabolites and are important intercellular communication controllers in several disorders. According to a vast amount of research, exosomes could support or inhibit tumor start and diffusion in a variety of solid and hematological malignancies by paracrine signaling. Exosomes are crucial therapeutic agents for a variety of illnesses, such

Совпадение в полном тексте источника
… Exosome removal from the circulation (via plasmapheresis), prevention of exosome production (via DMA), exosome suppression (via silencing of targeting ESCRT proteins or GTP-ase Rab27A), prevention of endolysosomal contents functions (via Proton pump inhibitors (PPI), and prevention of exosome uptake …

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive ther

Совпадение в полном тексте источника
… Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab . J Dermatolog Treat 2017 ; 28 : 564 – 566 . 28084106 10.1080/09546634.2017.1282599 118 Cartin-Ceba R Peikert T Ashrani A , et al . …

Hematopoietic Tumors

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis.

Myasthenia gravis (MG) is a disorder of neuromuscular junction transmission that is mediated by autoantibodies and depends on T cell help, causing fatigable muscle weakness. Limitations of conventional first-line treatments, including long-term adverse effects and inadequate control of refractory disease, have driven targeted therapy to the forefront of MG research. This narrative review summarizes second-line and later-line targeted biological and cellular therapies, covering agents directedat B and T cells, complement inhibitors, neonatal Fc receptor (FcRn) antagonists and cytokine inhibitor

Совпадение в полном тексте источника
… Therapeutic plasmapheresis: seven year experience of an intensive care unit in portugal. Acta Med Port . 2022;35(3):176–183. doi: 10.20344/amp.14266 11. Fuchs K, Rummler S, Ries W, et al. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. …

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Defibrotide, which is approved for treating hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS), exhibits pleiotropic anti-inflammatory, anti-thrombotic, and fibrinolytic properties, conferring broad endothelial protective effects. Given these mechanisms, defibrotide has potential utility in various conditions involving endothelial injury or activation. In this review we outline the endothelial-protective mechanisms of defibrotide and comprehensively summarize current evidence supporting its applications in hematologic malignancies, including the prevention and treatment

Совпадение в полном тексте источника
… Additionally, a retrospective analysis of 31 patients with TA-TMA who were treated with DF ± plasmapheresis ± rituximab showed a 61% overall response rate (100% in low-risk, 25% in high-risk patients), although outcomes were poor [ 126 ]. 3.4. …

Adeno-associated virus as a delivery vector for gene therapy of human diseases.

Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand has created challenges for the existing manufacturing methods. Seven rAAV-based gene therapy products have received regulatory approval, but there continue to be concerns about safely using high-dos

Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.

Recent advancements in cancer treatment, including targeted therapy, tailored vaccines, immunotherapy, and bacteriotherapy, have demonstrated remarkable potential in addressing various types of cancer. However, the pursuit of novel therapeutic strategies remains challenged by significant obstacles, including toxicity to healthy tissues, limited penetration into malignant tissues, and the potential for tumor cell resistance to pharmacological agents. This study explored the potential of tailored vaccinations, immunotherapy, CRISPR/Cas9, and bacteriotherapy for cancer treatment. Randomized and n

Совпадение в полном тексте источника
… Neurologic and cardiac toxicities are medical emergencies, treated immediately with high-dose intravenous steroids, sometimes alongside intravenous immunoglobulin or plasmapheresis. In these cases, rechallenge with ICIs is generally not safe [ 92 ]. …

Therapies for Chronic Allograft Rejection.

Remarkable advances have been made in the pathophysiology, diagnosis, and treatment of antibody-mediated rejection (ABMR) over the past decades, leading to improved graft outcomes. However, long-term failure is still high and effective treatment for chronic ABMR, an important cause of graft failure, has not yet been identified. Chronic ABMR has a relatively different phenotype from active ABMR and is a slowly progressive disease in which graft injury is mainly caused by de novo donor specific antibodies (DSA). Since most trials of current immunosuppressive therapies for rejection have focused

Совпадение в полном тексте источника
… One small retrospective study from Taiwan showed that aggressive treatment which included double-filtration plasmapheresis and one or more of the followings: rituximab, intravenous immunoglobulin (IVIG), antithymocyte globulin, bortezomib, or methylprednisolone pulse therapy, especially at the early …

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidiscip

Совпадение в полном тексте источника
… As with the approach to any electrolyte disorder, the first step after careful history taking and clinical examination is to exclude obvious causes such as dilution ( e.g. by massive fluid resuscitation, dialysis, plasmapheresis), spurious hypophosphatemia (from e.g. drug interference like amphotericin …

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.

Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma). In addition, it is being explored as a treatment option for solid tumors. As of 31 March 2022, seven CAR-T therapies for hematological malignancies have been approved worldwide. Although CAR-T therapy is an effective treatment for many malignancies, it also causes adverse effects. The incidence of cytokine release syndrome (CRS), the most common adverse reaction after infusion of CAR-T ce

Совпадение в полном тексте источника
… A 23-year-old man with a typical CRS response was effectively controlled with dexamethasone (10 mg, q6h) and plasmapheresis after failing to control his condition with glucocorticoids and tocilizumab ( Xiao et al., 2019 ). …

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. Given its unique natural course, designing an ideal trial design for MG has been wrought with difficulties and evidence in favour of several of the conventional agents is weak as per current standards. Despite this, acetylcholinesterases and corticosteroids have remained the cornerstones of treatment for several decades with intravenous immuno

The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas secondary antibody deficiency may arise as a consequence of underlying conditions or medication use. On a global level, malnutrition, HIV, and malaria are major causes of secondary immunodeficiency. In this review we consider secondary antibody deficiency, for which common causes include hematological malignancies, such as chronic lymphocytic leukemia or multiple myeloma, and their treatment, protein-losing states, and side

Совпадение в полном тексте источника
… Pohl MA, Lan S, Berl T, Lupus Nephritis Collaborative Study Group PLasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann Intern Med. (1991) 114:924–9. 10.7326/0003-4819-114-11-924 11. Agostini C, Blau IW, Kimby E, Plesner T. …

Abstracts of the ICARE 2024 78th SIAARTI National Congress

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.

Cell and gene therapies, including CAR T-cells, CRISPR-based genome editing, and next-generation viral and non-viral delivery platforms, are transforming treatment paradigms across cancer, rare genetic disorders, immune dysregulation, and neurodegenerative disease. These therapies offer curative potential but also present safety challenges owing to prolonged biological activity, systemic immune engagement, and lasting genomic alterations. This review examines the range of related toxicities, including immune complications, genotoxicity, and organ-specific effects, with attention to atypical pr

Совпадение в полном тексте источника
… Immunomodulatory therapies, primarily IVIG or plasmapheresis, are the mainstays of treatment. Recognizing these complications as immune-mediated rather than purely neurologic highlights the need for interdisciplinary management and LTFU in CGT recipients. …

The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.

In order to effectively manage and cure cancer we should move beyond the general view of cancer as a random process of genetic alterations leading to uncontrolled cell proliferation or simply a predictable evolutionary process involving selection for traits that increase cell fitness. In our view, cancer is a systemic disease that involves multiple interactions not only among cells within tumors or between tumors and surrounding tissues but also with the entire organism and its internal "milieu". We define the internal body climate as an emergent property resulting from spatial and temporal in

Совпадение в полном тексте источника
… Recently, removal of circulating soluble and PD-L1-positive extracellular vesicles from periphery through plasmapheresis (i.e., a manipulation of the internal climate) has been developed as a therapeutic intervention in melanoma, as an adjunctive of immunotherapy ( 90 ). 3.2.1.7 Oxygen Oxygen is an …

Резюме докладов 38th - ежегодное собрание общества общей внутренней медицины.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

17th Конгресс ЕВНОС: Милан, Италия, 4–6 Июнь, 2026 года

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… During the study, she experienced two further episodes of optic neuritis requiring high-dose corticosteroids, one of which additionally required plasmapheresis and intravenous immunoglobulins. Following the 30th dose of rozanolixizumab, she presented with blurred vision in the right eye. …